246 related articles for article (PubMed ID: 3973533)
1. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.
Holzmann B; Johnson JP; Kaudewitz P; Riethmüller G
J Exp Med; 1985 Feb; 161(2):366-77. PubMed ID: 3973533
[TBL] [Abstract][Full Text] [Related]
2. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
3. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
4. Growth and phenotypic characteristics of human nevus cells in culture.
Mancianti ML; Herlyn M; Weil D; Jambrosic J; Rodeck U; Becker D; Diamond L; Clark WH; Koprowski H
J Invest Dermatol; 1988 Feb; 90(2):134-41. PubMed ID: 2828480
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
6. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
[TBL] [Abstract][Full Text] [Related]
7. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
8. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
9. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
[TBL] [Abstract][Full Text] [Related]
10. A murine monoclonal antibody, MoAb HMSA-5, against a melanosomal component highly expressed in early stages, and common to normal and neoplastic melanocytes.
Der JE; Dixon WT; Jimbow K; Horikoshi T
Br J Cancer; 1993 Jan; 67(1):47-57. PubMed ID: 7678981
[TBL] [Abstract][Full Text] [Related]
11. Mouse monoclonal antibody (FKH1) detecting human melanoma-associated antigens.
Fukaya T; Hashimoto K; Eto H; Mehregan A
Cancer Res; 1986 Oct; 46(10):5195-200. PubMed ID: 3756874
[TBL] [Abstract][Full Text] [Related]
12. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
13. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
[TBL] [Abstract][Full Text] [Related]
14. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.
Holzmann B; Bröcker EB; Lehmann JM; Ruiter DJ; Sorg C; Riethmüller G; Johnson JP
Int J Cancer; 1987 Apr; 39(4):466-71. PubMed ID: 3104215
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
16. Transformation of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40 hybrid virus.
Jambrosic J; Mancianti ML; Ricciardi R; Sela BA; Koprowski H; Herlyn M
Int J Cancer; 1989 Dec; 44(6):1117-23. PubMed ID: 2558080
[TBL] [Abstract][Full Text] [Related]
17. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
Houghton AN; Eisinger M; Albino AP; Cairncross JG; Old LJ
J Exp Med; 1982 Dec; 156(6):1755-66. PubMed ID: 7175440
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.
Orchard GE
Histochem J; 2000 Aug; 32(8):475-81. PubMed ID: 11095072
[TBL] [Abstract][Full Text] [Related]
19. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
Herlyn M; Guerry D; Koprowski H
J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
Guerry D; Alexander MA; Elder DE; Herlyn MF
J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]